ArticleJournal of cardiology cases2026
Management of pericardial effusion with andexanet alfa during epicardial ventricular tachycardia ablation.
Article in Journal of cardiology cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Andexanet alfa, a reversal agent for factor Xa inhibitors, is rarely used during catheter ablation procedures. We describe a case in which andexanet alfa was effective to manage hemorrhagic pericardial effusion during epicardial ablation for ventricular tachycardia. After the administration of andexanet alfa, the therapeutic range of activated clotting times was difficult to achieve despite heparin administration. The procedure was completed safely by focusing on epicardial targets with minimal endocardial manipulation. Specific consideration of anticoagulation strategies is required in patients with hemorrhagic complications during ablation procedure. Learning objective: This case presents the first reported use of andexanet alfa during catheter ablation for ventricular arrhythmias and emphasizes the importance of tailoring procedural strategies to each case, including consideration of the arrhythmogenic substrate location, to avoid thromboembolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.